BUSINESS
Nippon Shinyaku, Pfizer Japan Sign Deal for Promotional Activities for Tramal
Nippon Shinyaku and Pfizer Japan announced on September 30 that the two companies entered into an exclusive sales promotion deal in Japan for Nippon Shinyaku’s cancer pain and chronic pain treatment Tramal Capsule (tramadol) and its investigational long-acting formulation NS-24…
To read the full story
BUSINESS
- NEC Crafts Data Platform to Advance Personalized Cancer Vaccine Program
October 28, 2025
- Shionogi Sees Flat 1H Results, Gains Domestic Support from Torii
October 28, 2025
- Novo to End Sales of Victoza in Japan, Fourth GLP-1 to Exit Market
October 28, 2025
- Eisai, Biogen Win Conditional Nod for Leqembi in Canada
October 28, 2025
- J&J Files for 4-Week SC Dosing of Rybrevant in Japan
October 28, 2025
In the dynamic pharmaceutical landscape, especially within the nuanced Japanese market, leadership hinges on acute awareness. This transcends surface-level observations, demanding a deep understanding of regulatory shifts, cultural sensitivities, and evolving patient needs. For leaders in this sector, particularly those…






